Entos (Now Iambic) Presents Latest AI-Driven Drug Discovery Advances at NeurIPS 2022
SAN DIEGO, CA – The Entos, Inc Machine Learning team will present its latest advances in AI-driven technologies to improve drug discovery at the 36th Conference on Neural Information Processing Systems (NeurIPS), a premier conference and venue for machine learning and AI science.
Head of Machine Learning Matthew Welborn will join biotech and AI industry leaders to discuss “The Landing of AI for Science and the Future of AI for Science in Industry” on Friday, December 2. He will discuss Entos’s disruption of drug discovery with a cutting-edge platform that integrates novel physics-informed AI design with high-throughput experimentation. Entos is advancing a pipeline of oncology therapeutics, addressing urgent patient need at the pace of program-launch-to-clinic in two years.
Additionally, Entos collaborator Zhuoran Qiao from the California Institute of Technology will describe dynamic-backbone protein-ligand structure prediction using multiscale generative diffusion models. This recently announced work (arXiv:2209.15171), a collaboration involving scientists from NVIDIA, Caltech and Entos, demonstrates that multiscale generative diffusion models with equivariant transformers are effective for protein-ligand structure prediction. Zhuoran’s presentation will be part of the Workshop on Machine Learning in Structural Biology (www.mlsb.io) on Saturday, December 3.
“Participation in NeurIPS and other leading venues for AI and automation is part of the Entos mission to provide leadership and innovation at the interface of drug discovery and technology.”
- Fred Manby, Entos co-founder and CTO
Entos is disrupting drug discovery with a cutting-edge platform that integrates novel physics-informed AI design with high-throughput experimentation. Headquartered in La Jolla, CA, the Entos team includes Nobel laureates, renowned scientists, and industry leaders in machine learning, laboratory automation, and biotechnology. Entos is advancing a pipeline of oncology therapeutics, addressing urgent patient need at the pace of program-launch-to-clinic in two years. Learn more about Entos' team, platform, and pipeline at www.entos.ai.
Sard Verbinnen & Co.